The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Increase Is Anticipated For The Prolastin, Prolastin-C Market Over The 2026–2030 Period?
Historical expansion was driven by the authorization for alpha-1 antitrypsin deficiency, its proven clinical effectiveness in protecting lungs, widespread acceptance by specialist pulmonologists, a scarcity of other treatment options, and the readiness of plasma-derived protein supplies.
During the forecast period, the observed growth is linked to enhanced genetic screening rates, a heightened understanding of alpha-1 antitrypsin (AAT) deficiency, the proliferation of specialized care facilities, an increasing burden of respiratory diseases, and improved patient compliance with long-term treatments.
Key developments anticipated during the forecast period include the increasing adoption of alpha-1 replacement therapy, the broader availability of long-term lung protection treatments, a rise in the diagnosis of AAT deficiency, the implementation of hospital-based augmentation therapy, and a concerted effort towards preventing the progression of the disease.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19920&type=smp
Which Economic Or Industry Drivers Are Impacting The Prolastin, Prolastin-C Market?
The rising occurrence of respiratory infections is anticipated to drive the expansion of the prolastin, prolastin-C market. Respiratory infections involve ailments impacting the respiratory system, encompassing the nose, throat, airways, and lungs, triggered by diverse pathogens such as viruses, bacteria, fungi, or other microbes. The escalation in these infections stems from elements like novel viral strains, seasonal shifts, compromised immune systems, compounded by environmental contamination and enhanced human movement. Prolastin and Prolastin-C, as alpha-1 antitrypsin (AAT) replacement therapies, aid in addressing respiratory conditions, especially chronic obstructive pulmonary disease (COPD) linked to AAT deficiency. They achieve this by restoring the inadequate AAT protein, which consequently diminishes lung inflammation, safeguards against tissue harm from protease activity, and enhances lung function and overall respiratory well-being for individuals with this genetic ailment. For example, in October 2024, the National Asthma Council, an Australia-based non-profit organization, reported 474 asthma-related deaths in Australia in 2023, including 325 females and 149 males. This total is nearly identical to the 473 asthma-related deaths in 2022, indicating a stable trend in asthma mortality across both years. Consequently, the growing frequency of respiratory infections is propelling the expansion of the prolastin, prolastin-C market.
How Is The Prolastin, Prolastin-C Market Segmented Across Key Categories?
The prolastin, prolastin-c market covered in this report is segmented –
1) By Type: 20ml, 40ml
2) By Indication: Alpha-1 Antitrypsin Deficiency, Respiratory Health, Chronic Lung Disease, Genetic Disorders
3) By Application: Hospital, Pharmacy
Which Upcoming Trends Are Expected To Influence The Prolastin, Prolastin-C Market?
Leading companies operating within the peolastin and prolastin-C market are concentrating on clinical trials to assess the safety and efficacy of pharmaceuticals. Clinical trials are research studies conducted to evaluate the safety, effectiveness, and potential adverse effects of new treatments, drugs, or medical devices on human participants. For instance, in July 2023, Grifols SA, a Spain-based pharmaceutical company, announced it had achieved its goal of enrolling 339 patients in the SPARTA (Study of ProlAstin-c Randomized Therapy with Alpha-1 Augmentation) phase 3 clinical trial. The primary goal of this trial is to ascertain if patients with emphysema resulting from alpha-1-antitrypsin (AAT) deficiency (alpha-1) experience a slower rate of lung tissue loss when they receive weekly treatment with two different dose regimens of Grifols Prolastin-C. This effort is designed to evaluate Prolastin-C’s effectiveness in reducing emphysema progression in alpha-1 antitrypsin deficiency (AATD) patients by increasing AAT protein levels through the weekly administration of two active doses (60 and 120 mg/kg) when compared to a placebo.
Who Are The Dominant Players Shaping The Prolastin, Prolastin-C Market Landscape?
Major companies operating in the prolastin, prolastin-c market are Grifols SA
Read the full prolastin, prolastin-c market report here:
https://www.thebusinessresearchcompany.com/report/prolastin-prolastin-c-global-market-report
What Are The Top-Performing Regions Within The Prolastin, Prolastin-C Market?
North America was the largest region in the prolastin or prolastin-C market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prolastin, prolastin-c market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Prolastin, Prolastin-C Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=19920&type=smp
Browse Through More Reports Similar to the Global Prolastin, Prolastin-C Market 2026, By The Business Research Company
Proanthocyanidins Market Report 2026
https://www.thebusinessresearchcompany.com/report/proanthocyanidins-global-market-report
Isotretinoin Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/isotretinoin-drugs-global-market-report
Retinol Market Report 2026
https://www.thebusinessresearchcompany.com/report/retinol-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model